40 results on '"Paturel, Carine"'
Search Results
2. S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS
3. IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies
4. Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists
5. CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer
6. Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control
7. Plasmacytoid Dendritic Cells Mediate Oral Tolerance
8. Ikaros is required for plasmacytoid dendritic cell differentiation
9. Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells
10. Une nouvelle génération d’immunothérapies ciblant la voie CD39/CD73/adénosine pour favoriser la réponse immunitaire anti-tumorale
11. Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells
12. Abstract 2713: Preclinical development of first-in-class antibodies targeting Siglec-9 immune checkpoint for cancer immunotherapy
13. Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy
14. Abstract 2718: Preclinical development of humanized CD39 and CD73 blocking antibodies targeting the ATP/adenosine immune checkpoint pathway for cancer immunotherapy
15. A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
16. Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial
17. First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results
18. Abstract 2344: Discovery and characterization of new original blocking antibodies targeting the CD73 immune checkpoint for cancer immunotherapy
19. Abstract 1491: IPH4301, an antibody targeting MICA and MICB exhibits potent cytotoxic activity and immunomodulatory properties for the treatment of cancer
20. The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
21. IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma
22. Abstract 651: Ex vivo and in vivo characterization of IPH4102, a humanized anti-KIR3DL2 antibody for the treatment of cutaneous T-cell lymphomas
23. Abstract 5037: Targeting MICA with therapeutic antibodies for the treatment of cancer
24. Abstract 4733: Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T Cell Lymphomas .
25. Novel therapeutic and diagnostic antibodies against KIR3DL2, a unique tumor antigen overexpressed on subtypes of T cell lymphomas
26. Targeting MICA with therapeutic antibodies for the treatment of cancer
27. Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic
28. TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer
29. Poly(I:C) induces intense expression of c-IAP2 and cooperates with an IAP inhibitor in induction of apoptosis in cancer cells
30. Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands
31. Production of type I interferons
32. Type I interferon dependence of plasmacytoid dendritic cell activation and migration
33. Flexibility of Mouse Classical and Plasmacytoid-derived Dendritic Cells in Directing T Helper Type 1 and 2 Cell Development
34. The Development of Murine Plasmacytoid Dendritic Cell Precursors Is Differentially Regulated by FLT3-ligand and Granulocyte/Macrophage Colony-Stimulating Factor
35. Interferon α/β and Interleukin 12 Responses to Viral Infections
36. Virus-induced Interferon α Production by a Dendritic Cell Subset in the Absence of Feedback Signaling In Vivo
37. Poly(I:C) induces intense expression of c-IAP2 andcooperates with an IAP inhibitor in induction ofapoptosis in cancer cells.
38. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
39. Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo.
40. Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.